CN109221898A - 一种含低聚木糖的谷物粉及其制备方法和应用 - Google Patents
一种含低聚木糖的谷物粉及其制备方法和应用 Download PDFInfo
- Publication number
- CN109221898A CN109221898A CN201810564003.6A CN201810564003A CN109221898A CN 109221898 A CN109221898 A CN 109221898A CN 201810564003 A CN201810564003 A CN 201810564003A CN 109221898 A CN109221898 A CN 109221898A
- Authority
- CN
- China
- Prior art keywords
- parts
- oligosaccharide
- powder
- xylo
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 title claims abstract description 55
- 239000000428 dust Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 239000000843 powder Substances 0.000 claims abstract description 54
- 235000013339 cereals Nutrition 0.000 claims abstract description 43
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 36
- 206010012601 diabetes mellitus Diseases 0.000 claims abstract description 34
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 24
- 240000000249 Morus alba Species 0.000 claims abstract description 19
- 235000008708 Morus alba Nutrition 0.000 claims abstract description 19
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 19
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 19
- 229920001202 Inulin Polymers 0.000 claims abstract description 17
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 claims abstract description 17
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 17
- 229940029339 inulin Drugs 0.000 claims abstract description 17
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 17
- 244000068988 Glycine max Species 0.000 claims abstract description 16
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 16
- 244000247812 Amorphophallus rivieri Species 0.000 claims abstract description 15
- 235000001206 Amorphophallus rivieri Nutrition 0.000 claims abstract description 15
- 239000004375 Dextrin Substances 0.000 claims abstract description 15
- 229920001353 Dextrin Polymers 0.000 claims abstract description 15
- 229920002581 Glucomannan Polymers 0.000 claims abstract description 15
- 229920002752 Konjac Polymers 0.000 claims abstract description 15
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 claims abstract description 15
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims abstract description 15
- 235000019425 dextrin Nutrition 0.000 claims abstract description 15
- 239000000252 konjac Substances 0.000 claims abstract description 15
- 235000010485 konjac Nutrition 0.000 claims abstract description 15
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 15
- 239000000811 xylitol Substances 0.000 claims abstract description 15
- 235000010447 xylitol Nutrition 0.000 claims abstract description 15
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims abstract description 15
- 229960002675 xylitol Drugs 0.000 claims abstract description 15
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 claims abstract description 14
- 229940046240 glucomannan Drugs 0.000 claims abstract description 14
- 244000241838 Lycium barbarum Species 0.000 claims abstract description 12
- 235000015459 Lycium barbarum Nutrition 0.000 claims abstract description 12
- 235000015468 Lycium chinense Nutrition 0.000 claims abstract description 12
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 12
- WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 claims abstract description 12
- 235000004879 dioscorea Nutrition 0.000 claims abstract description 12
- 235000013312 flour Nutrition 0.000 claims abstract description 12
- 235000013305 food Nutrition 0.000 claims abstract description 12
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 12
- 229940099596 manganese sulfate Drugs 0.000 claims abstract description 12
- 239000011702 manganese sulphate Substances 0.000 claims abstract description 12
- 235000007079 manganese sulphate Nutrition 0.000 claims abstract description 12
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims abstract description 12
- 239000002994 raw material Substances 0.000 claims abstract description 12
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 12
- 229940046009 vitamin E Drugs 0.000 claims abstract description 12
- 239000011709 vitamin E Substances 0.000 claims abstract description 12
- 239000011670 zinc gluconate Substances 0.000 claims abstract description 12
- 235000011478 zinc gluconate Nutrition 0.000 claims abstract description 12
- 229960000306 zinc gluconate Drugs 0.000 claims abstract description 12
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 10
- 239000011669 selenium Substances 0.000 claims description 20
- 239000011651 chromium Substances 0.000 claims description 18
- 235000002722 Dioscorea batatas Nutrition 0.000 claims description 12
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims description 12
- 240000001811 Dioscorea oppositifolia Species 0.000 claims description 12
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims description 12
- 201000001352 cholecystitis Diseases 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 6
- 230000003345 hyperglycaemic effect Effects 0.000 claims description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 5
- 229910052804 chromium Inorganic materials 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 238000010992 reflux Methods 0.000 claims description 5
- 239000011701 zinc Substances 0.000 claims description 5
- 229910052725 zinc Inorganic materials 0.000 claims description 5
- 238000009098 adjuvant therapy Methods 0.000 claims description 4
- 238000000605 extraction Methods 0.000 claims description 4
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 241000219780 Pueraria Species 0.000 claims description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 238000000227 grinding Methods 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 238000005507 spraying Methods 0.000 claims description 2
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims 2
- NAOLWIGVYRIGTP-UHFFFAOYSA-N 1,3,5-trihydroxyanthracene-9,10-dione Chemical compound C1=CC(O)=C2C(=O)C3=CC(O)=CC(O)=C3C(=O)C2=C1 NAOLWIGVYRIGTP-UHFFFAOYSA-N 0.000 claims 1
- 235000009754 Vitis X bourquina Nutrition 0.000 claims 1
- 235000012333 Vitis X labruscana Nutrition 0.000 claims 1
- 240000006365 Vitis vinifera Species 0.000 claims 1
- 235000014787 Vitis vinifera Nutrition 0.000 claims 1
- 238000005516 engineering process Methods 0.000 abstract description 3
- 239000008280 blood Substances 0.000 description 55
- 210000004369 blood Anatomy 0.000 description 55
- 239000008103 glucose Substances 0.000 description 39
- 230000000694 effects Effects 0.000 description 31
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 29
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 24
- 239000003814 drug Substances 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 13
- 102000004877 Insulin Human genes 0.000 description 12
- 108090001061 Insulin Proteins 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 229940125396 insulin Drugs 0.000 description 12
- 230000006870 function Effects 0.000 description 10
- 150000002632 lipids Chemical class 0.000 description 9
- 229910052711 selenium Inorganic materials 0.000 description 9
- 240000004270 Colocasia esculenta var. antiquorum Species 0.000 description 8
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 8
- 150000004676 glycans Chemical class 0.000 description 8
- 229920001282 polysaccharide Polymers 0.000 description 8
- 239000005017 polysaccharide Substances 0.000 description 8
- 230000000291 postprandial effect Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 235000005911 diet Nutrition 0.000 description 6
- 230000037213 diet Effects 0.000 description 6
- 210000000496 pancreas Anatomy 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 5
- 230000002218 hypoglycaemic effect Effects 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 239000006041 probiotic Substances 0.000 description 4
- 235000018291 probiotics Nutrition 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 208000017442 Retinal disease Diseases 0.000 description 3
- 206010038923 Retinopathy Diseases 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 230000002641 glycemic effect Effects 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 230000001771 impaired effect Effects 0.000 description 3
- 230000010354 integration Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 2
- 102000040350 B family Human genes 0.000 description 2
- 108091072128 B family Proteins 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010018473 Glycosuria Diseases 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 108010028554 LDL Cholesterol Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- HIMXGTXNXJYFGB-UHFFFAOYSA-N alloxan Chemical compound O=C1NC(=O)C(=O)C(=O)N1 HIMXGTXNXJYFGB-UHFFFAOYSA-N 0.000 description 2
- 230000002929 anti-fatigue Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 235000013325 dietary fiber Nutrition 0.000 description 2
- LXBIFEVIBLOUGU-JGWLITMVSA-N duvoglustat Chemical compound OC[C@H]1NC[C@H](O)[C@@H](O)[C@@H]1O LXBIFEVIBLOUGU-JGWLITMVSA-N 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 239000001573 invertase Substances 0.000 description 2
- 235000011073 invertase Nutrition 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 235000019155 vitamin A Nutrition 0.000 description 2
- 239000011719 vitamin A Substances 0.000 description 2
- 235000019158 vitamin B6 Nutrition 0.000 description 2
- 229940045997 vitamin a Drugs 0.000 description 2
- 229940011671 vitamin b6 Drugs 0.000 description 2
- 229960003487 xylose Drugs 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- BWWAFUZQSLIIIH-UHFFFAOYSA-N 2-phenyl-3H-chromen-3-id-4-one Chemical compound O1C(=[C-]C(=O)C2=CC=CC=C12)C1=CC=CC=C1 BWWAFUZQSLIIIH-UHFFFAOYSA-N 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 244000205754 Colocasia esculenta Species 0.000 description 1
- 235000006481 Colocasia esculenta Nutrition 0.000 description 1
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000194033 Enterococcus Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 1
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 208000017170 Lipid metabolism disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000022329 Protein metabolism disease Diseases 0.000 description 1
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- SRBFZHDQGSBBOR-LECHCGJUSA-N alpha-D-xylose Chemical compound O[C@@H]1CO[C@H](O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-LECHCGJUSA-N 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 230000001194 anti-hemostatic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- -1 carrotene Chemical class 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 208000004104 gestational diabetes Diseases 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007407 health benefit Effects 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 238000005213 imbibition Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 239000011812 mixed powder Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 125000003748 selenium group Chemical group *[Se]* 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000004003 subcutaneous fat Anatomy 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 229940046001 vitamin b complex Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 235000020795 whole food diet Nutrition 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/101—Addition of antibiotics, vitamins, amino-acids, or minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明属于食品技术领域,具体涉及一种含低聚木糖的谷物粉及其制备方法和应用。所述谷物粉,由以下原料重量百分比制成的:燕麦粉15%‑20%、山药粉10%‑15%、葛根粉8%‑12%、桑叶粉8%‑12%、抗性糊精6%‑10%、木糖醇6%‑10%、菊粉6%‑10%、L‑阿拉伯糖6%‑10%、枸杞粉3%‑7%、大豆肽2%‑5%、低聚木糖95粉2%‑5%、魔芋胶1%‑4%、维生素B60.1‰‑0.5‰、维生素E0.1‰‑0.5‰、富硒酵母2‰‑6‰、硫酸锰0.01‰‑0.05‰、葡萄糖酸锌0.02‰‑0.06‰、富铬酵母0.002‰‑0.004‰。本发明谷物粉可以辅助治疗2型糖尿病及其并发症。
Description
技术领域
本发明属于食品技术领域,具体涉及一种含低聚木糖的谷物粉及其制备方法和应用。
背景技术
糖尿病作为一种高发的代谢性疾病,主要是体内胰腺的胰岛器官分泌胰岛素不足,导致身体所摄取的糖分不能得到充分分解和吸收,致使体内血糖长期处于较高的水平。由于体内胰岛素分泌相对或绝对不足导致糖、脂肪和蛋白质代谢紊乱,患者以多饮、多食、多尿、身体消瘦为特征。随着人们生活水平的提高,糖尿病已成为继心脑血管疾病和恶性肿瘤之后,危害人类身体健康的第三大疾病。
目前用于糖尿病临床治疗的的药物包括中药和西药两大类。但是,多数用于治疗糖尿病的中药因其主要成分不足以降血糖,对糖尿病的控制效果有很大的局限性;而以胰岛素、磺脲素、双胍素为主的西药为单一降糖药,不能改善机体的其它机能,尤其对糖尿病并发症基本没有治疗效果,而且都存在不同程度的副作用。由于现代技术的问题,还没有可以完全根治糖尿病的方法。
糖尿病分1型糖尿病、2型糖尿病、妊娠糖尿病及其他特殊类型的糖尿病。在糖尿病患者中,2型糖尿病所占的比例约为90%。针对2型糖尿病患者,治疗的原则可以在控制血糖的基础上,尽量少地使用药物,在饮食上控制高血糖人群血糖波动水平,既满足2型糖尿病患者对营养的需求,又能够从饮食上辅助降低血糖升高水平,且食用非常方便。使用具有降血糖活性的天然食品资源,其往往含有多种协同成分的降血糖功能因子,而且对人体作用温和、持久,性质稳定,较少出现副作用,能对糖尿病及其并发症起到有效的辅助治疗作用。因此,开发一种具有辅助治疗2型糖尿病及其并发症的功能食品是亟需的。
发明内容
本发明的主要目的是提供一种含低聚木糖的谷物粉,其具有辅助降低血糖、增加肠道益生菌群、润肠通便、调节肠道健康的健康益处,从而达到辅助治疗2型糖尿病的作用。
为实现上述目的,本发明采用以下技术方案:
本发明目的之一,提供一种含低聚木糖的谷物粉,由以下原料及其重量份制成的:燕麦粉15-20份、山药粉10-15份、葛根粉8-12份、桑叶粉8-12份、抗性糊精6-10份、木糖醇6-10份、菊粉6-10份、L-阿拉伯糖6-10份、枸杞粉3-7份、大豆肽2-5份、低聚木糖95粉2-5份、魔芋胶1-4份、维生素B6 0.1-0.5份、维生素E 0.1-0.5份、富硒酵母2-6份、硫酸锰0.01-0.05份、葡萄糖酸锌0.02-0.06份、富铬酵母0.002-0.004份。
在本发明优选的方案中,所述含低聚木糖的谷物粉由以下原料及其重量份制成的:燕麦粉18份、山药粉12份、葛根粉9份、桑叶粉8份、抗性糊精8份、木糖醇7份、菊粉6份、L-阿拉伯糖6份、枸杞粉5份、大豆肽4份、低聚木糖95粉4份、魔芋胶3份、维生素B6 0.3份、维生素E 0.3份、富硒酵母4份、硫酸锰0.05份、葡萄糖酸锌0.05份、富铬酵母0.004份。
在本发明优选的方案中,所述含低聚木糖的谷物粉由以下原料及其重量份制成的:燕麦粉16份、山药粉13份、葛根粉10份、桑叶粉10份、抗性糊精6份、木糖醇8份、菊粉8份、L-阿拉伯糖8份、枸杞粉6份、大豆肽3份、低聚木糖95粉5份、魔芋胶2份、维生素B6 0.1份、维生素E 0.5份、富硒酵母3份、硫酸锰0.03份、葡萄糖酸锌0.04份、富铬酵母0.003份。
燕麦富含膳食纤维和维生素B群,具有促进肠胃蠕动,利于排便,热量低,升糖指数低,降脂降糖等作用。燕麦中的β-葡聚糖可减缓血液中葡萄糖含量的增加,预防和控制肥胖症、糖尿病及心血管疾病。1997年美国FDA认定燕麦为功能性食物,具有降低胆固醇、平稳血糖的功效。
山药中含有大量淀粉及蛋白质、可溶性纤维素、山药多糖、B族维生素等。山药中可溶性纤维,能推迟胃内食物的排空,控制饭后血糖升高;还能助消化、降血糖。山药中的山药多糖对降血糖、血脂效果非常明显。此外,山药还具有防止心血管系统脂肪沉淀,保持血管的弹性,防止动脉粥样硬化过早发生,减少皮下脂肪沉积等作用。
葛根含有人体需要的10多种氨基酸和10多种微量元素;葛根总黄酮能减慢心率,降低心脏总外周阻力,减少心肌耗氧量,提高心肌工作效率;葛根素具有明显扩张冠状血管的作用,能使冠血流量增加,血管阻力降低。
桑叶富含黄酮、酚类、氨基酸、有机酸、胡萝卜素、维生素及多种人体必需的微量元素,含有一种其他动植物所没有的生物碱1-脱氧野霉素“DNJ”,能抑制蔗糖酶、麦芽糖酶、a-葡萄糖甘糖、a-淀粉酶的分解,能刺激胰岛素分泌,降低胰岛素分解速度。
葛根中的黄酮物质与桑叶中脱氧野尻霉素结合,可以形成一种新物质—洗胰清糖素,洗胰清糖素可以将血液中淤积的“毒糖”分解成微粒子,使其渗入到细胞内部转换成能量;同时双向调节血糖,恢复自身化糖本能;快速修复受损β细胞,使胰岛细胞再生,营养胰腺,增强人体免疫力。
抗性糊精含有抗人体消化酶作用的难消化成分,在消化道中不会被消化吸收,可直接进入大肠;其具有的高消化耐受性,低血糖指数,低胰岛素指数,低热量,防止龋齿,极易溶解等特性,可起到降血糖、降血脂和养护肠道的作用。
木糖醇属于低升糖指数食物,木糖醇在人体的代谢中不但不经过胰岛素,还能促进胰岛素的分泌,并且不增加血糖和尿糖,是糖尿病人良好的营养剂和辅助治疗剂。
菊粉是一种天然的水溶性膳食纤维,几乎不能被胃酸水解和消化,只有在结肠被有益微生物利用,从而改善肠道环境。它在肠道的上部不会被水解成单糖,因而不会升高血糖水平和胰岛素含量。研究表明,空腹血糖的降低是低聚果糖在结肠发酵所产生的短链脂肪酸的结果。食入菊粉还可有效降低血清总胆固醇(TC)和低密度脂蛋白胆固醇(LDL-C),提高高密度脂蛋白/低密度脂蛋白比率,改善血脂状况。此外,摄入菊粉后能增强胃肠道蠕动,提高肠胃功能,增加消化和食欲,提高机体免疫力。
L-阿拉伯糖能有效抑制人体小肠黏膜蔗糖酶的活性,进而阻止人体对蔗糖的分解吸收;还可有效控制血糖和减少脂肪的堆积,有预防高血脂、高血糖、肥胖和高血压等疾病作用。
枸杞中含有枸杞多糖,甜菜碱,枸杞色素等主要成分。其中枸杞多糖是一种水溶性多糖,是枸杞中最主要的活性成分,具有促进免疫、抗衰老、抗肿瘤、清除自由基、抗疲劳、抗辐射、保肝、生殖功能保护和改善等作用。研究发现,枸杞多糖能降低四氧嘧啶诱导的糖尿病兔血糖和血脂的水平,降低高脂饲料喂养大鼠的血脂和血糖水平。枸杞色素主要包括胡萝卜素、叶黄素和其他有色物质,而胡萝卜素具有抗氧化和作为维生素A的合成前体等重要的生理功能。
功能性低聚木糖是一种具有益生元功能的低聚糖。低聚木糖对双歧杆菌、乳酸菌等益生菌有高选择性增殖效果,对大肠杆菌、肠球菌、梭状芽孢杆菌等病原菌有明显的抑制作用。此外,低聚木糖可以促进药物吸收,提高其疗效,是糖尿病治疗的辅助食物。而低聚木糖与枸杞等中药复配联用具有降糖作用,可以产生更好的治疗效果。
大豆肽富含22种氨基酸,其中包含9种人体不能合成的必需氨基酸,营养丰富、容易吸收,且含有多种生物活性肽,具有多种生理活性,包括抗氧化、降血压、降低胆固醇、降血脂、抗疲劳、增强免疫等。
魔芋胶是从天然食用魔芋块茎里提取出的葡甘露聚糖,是一种大分子多糖,具有热量低,吸水性强、黏度大、膨胀率高的特点,能吸附胆固醇和胆汁酸,对抑制餐后血糖升高有明显效果。
B族维生素是推动体内代谢,把糖、脂肪、蛋白质等转化成热量时不可缺少的物质。维生素B6是人体脂肪和糖代谢的必需物质,与糖原、神经鞘磷脂和类固醇的代谢有关。维生素E在防治心脑血管疾病、肿瘤、糖尿病及其他并发症、中枢神经系统疾病、运动系统疾病、皮肤疾病等方面具有广泛的作用。维生素E是一种很重要的血管扩张剂和抗凝血剂;预防与治疗静脉曲张;防止血液的凝固,减少斑纹组织的产生。维生素的作用是相辅相成的,同时补充,能够发挥更有效的作用。
本发明在产品配方中添加多种维生素和矿物质用于调节机体机能。其中:
硒是胰岛β细胞可以分泌胰岛素,调节血糖,而硒具有保护胰岛β细胞的作用,硒缺乏可以导致β胰岛细胞受损,使血糖升高。富硒酵母是硒与酵母体内的蛋白质和多糖有机结合转化成为生物硒,从而消除了化学硒对人体的毒副反应和肠胃刺激,并且使硒能够更高效、更安全地被人体吸收利用。富硒酵母本身富含蛋白质、糖类和18种维生素,除可作为硒源使用外,还同时提供其它有益的营养素。
锰是多种酶的主要成分,能使酶活化,加速细胞内脂肪氧化,改善脂质代谢,并能减少肝脏内脂肪堆积。研究表明,补锰后有益于糖尿病的治疗,可明显降低糖尿病伴高血压病患者的血压水平,提高高密度脂蛋白(dPc),降低甘油三酯、胆固醇及低密度脂蛋白(cPc)的水平,从而能有效防治高脂血症及诱发动脉硬化,保护血管而且对预防糖尿病的并发症有作用。
锌可影响胰岛素的合成、分泌、储存、降解及生物活性;且锌对维生素A的代谢起重要作用,有利于视觉功能维持;适当补锌,可以有助于降低血脂,提高抗氧化能力。
铬是维持人体糖和脂肪代谢的重要因素,可以缓解胰岛素抵抗、调节血糖和血脂;富铬酵母是将酵母作为载体,培养出富集铬元素功能的可食用功能性酵母,酵母铬含有的生物活性铬人体吸收率高。富铬酵母具有增强胰岛素活性,控制血糖的作用;还能够降低血中胆固醇和甘油三酯的含量,预防心血管病。
本发明目的之二,提供一种如上述所述的含低聚木糖的谷物粉制备方法,步骤如下:取葛根、山药、枸杞、桑叶,混合粉碎,加水浸泡,回流提取,过滤得提取液,提取液经浓缩、喷雾干燥即可得到成品;然后与燕麦粉、L-阿拉伯糖、低聚木糖和菊粉、抗性糊精、木糖醇、L-阿拉伯糖、大豆肽、低聚木糖、魔芋胶、维生素B6、维生素E、富硒酵母、硫酸锰、葡萄糖酸锌、富铬酵母按比例混合,混匀,即得。
在本发明优选的方案中,所述药材粉碎粒度为20-30目。
在本发明优选的方案中,上述步骤中加水水量与葛根、山药、枸杞、桑叶的粉粹混合物的质量比为5-7:1,浸泡时间为30-60min。
在本发明优选的方案中,所述回流提取时间为30-40min。
本发明目的之三,提供一种所述的含低聚木糖的谷物粉在制备辅助降血糖功能食品中的应用。
在本发明优选的方案中,在制备辅助治疗2型糖尿病及其并发症功能食品中的应用。
在本发明进一步优选的方案中,所述2型糖尿病并发症为胆囊炎。
与现有技术相比,本发明具有以下优点:
(1)本发明通过科学配伍,选择数种药食同源的食品原料、低升糖指数谷物粉、配合低聚木糖等益生元,复配制作具有辅助降低血糖作用的产品,其中,添加的低聚木糖等益生元充分发挥双歧因子作用,能够显著增加肠道益生菌群数量,配合具有降血糖、提高免疫力的药食同源食品原料,减轻中药和西药服用的副作用,从而实现药食同源食品与益生菌一起共同发挥辅助降血糖的作用;
(2)本发明制备得到的辅助降血糖谷物粉口感好,无毒副作用,原料来源丰富,制备方法简单,可大规模进行生产,具有较好的经济效益和社会效益,可有效从饮食上改善高血糖人群血糖水平;并且可以辅助治疗2型糖尿病;
(3)本发明技术人员还意外发现,服用本发明谷物粉后对2型糖尿病并发症胆囊炎也具有很好的辅助治疗效果。
具体实施方式
应该指出,以下详细说明都是示例性的,旨在对本发明提供进一步的说明。除非另有指明,本文使用的所有技术和科学术语具有与本发明所属技术领域的普通技术人员通常理解的相同含义。
需要注意的是,这里所使用的术语仅是为了描述具体实施方式,而非意图限制根据本发明的示例性实施方式。如在这里所使用的,除非上下文另外明确指出,否则单数形式也意图包括复数形式,此外,还应当理解的是,当在本说明书中使用术语“包含”和/或“包括”时,其指明存在特征、步骤、操作和/或它们的组合。
结合具体实例对本发明作进一步的说明,以下实施例仅是为了解释本发明,并不对其内容进行限定。
实施例1一种含低聚木糖的谷物粉
所述含低聚木糖的谷物粉,由以下原料及其重量份制成的:燕麦粉20份、山药粉15份、葛根粉12份、桑叶粉12份、抗性糊精10份、木糖醇10份、菊粉10份、L-阿拉伯糖10份、枸杞粉7份、大豆肽5份、低聚木糖95粉5份、魔芋胶14份、维生素B6 0.5份、维生素E 0.5份、富硒酵母6份、硫酸锰0.05份、葡萄糖酸锌0.06份、富铬酵母0.004份。
实施例2一种含低聚木糖的谷物粉
所述含低聚木糖的谷物粉,由以下原料及其重量份制成的:燕麦粉15份、山药粉10份、葛根粉8份、桑叶粉8份、抗性糊精6份、木糖醇6份、菊粉6份、L-阿拉伯糖6份、枸杞粉3份、大豆肽2份、低聚木糖95粉2份、魔芋胶1份、维生素B60.1份、维生素E0.1份、富硒酵母2份、硫酸锰0.01份、葡萄糖酸锌0.02份、富铬酵母0.002份。
实施例3一种含低聚木糖的谷物粉
所述含低聚木糖的谷物粉,由以下原料及其重量份制成的:燕麦粉18份、山药粉12份、葛根粉9份、桑叶粉8份、抗性糊精8份、木糖醇7份、菊粉6份、L-阿拉伯糖6份、枸杞粉5份、大豆肽4份、低聚木糖95粉4份、魔芋胶3份、维生素B60.3份、维生素E0.3份、富硒酵母4份、硫酸锰0.05份、葡萄糖酸锌0.05份、富铬酵母0.004份。
实施例4一种含低聚木糖的谷物粉
所述含低聚木糖的谷物粉由以下原料及其重量份制成的:燕麦粉16份、山药粉13份、葛根粉10份、桑叶粉10份、抗性糊精6份、木糖醇8份、菊粉8份、L-阿拉伯糖8份、枸杞粉6份、大豆肽3份、低聚木糖95粉5份、魔芋胶2份、维生素B6 0.1份、维生素E 0.5份、富硒酵母3份、硫酸锰0.03份、葡萄糖酸锌0.04份、富铬酵母0.003份。
对比例1一种含低聚木糖的谷物粉
与实施例3的区别在于,所述含低聚木糖的谷物粉中由玉竹提取物代替葛根粉,其它均与实施例3相似。
对比例2一种含低聚木糖的谷物粉
与实施例3的区别在于,所述含低聚木糖的谷物粉中由玉米芯粉代替山药粉,其它均与实施例3相似。
对比例3一种含低聚木糖的谷物粉
与实施例3的区别在于,所述含低聚木糖的谷物粉中由大豆蛋白代替大豆肽,其它均与实施例3相似。
实施例5一种含低聚木糖的谷物粉制备方法
所述含低聚木糖的谷物粉制备方法,步骤如下:取葛根、山药、枸杞、桑叶,混合粉碎至碎粒度为20-30目,加水浸泡,加水水量与葛根、山药、枸杞、桑叶的粉粹混合物的质量比为5-7:1,浸泡时间为30-60min,回流提取30-40min,过滤得提取液,提取液经浓缩、喷雾干燥即可得到成品;然后与燕麦粉、L-阿拉伯糖、低聚木糖和菊粉、抗性糊精、木糖醇、L-阿拉伯糖、大豆肽、低聚木糖、魔芋胶、维生素B6、维生素E、富硒酵母、硫酸锰、葡萄糖酸锌、富铬酵母按比例混合,混匀,即得。
试验例1
取出生4周后断乳大鼠体重60-80g,每组20只,共100只,同时采用实施例1~4及对比例1~3配方10倍剂量即高剂量组和实施例1~4及对比例1-3低剂量组及空白对照组,用去离子水溶解样品,经口灌胃给予受试动物,灌胃量为1mL/100g,每天2次,喂养6周。
毒性实验结果:灌胃给药后观察四周,均未发现实验动物死亡,本发明的组合物急性毒性低;测定各项指标,观察和测定项目包括如外观体症和行为活动、分泌物、粪便性状,血液的常规指标和生化指标,系统尸检及脏器系数和组织学检查等内容,结果表明:用不同剂量给大鼠连续口服,对大鼠的进食量和体重增长均无影响,对肝肾功能均未发现明显毒性作用,对血常规、血生化、尿液生化及骨髓片等均未见明显影响。
同时,实验结束后对各组大鼠空腹血糖水平和餐后2小时血糖值(mmol/L,M±SD)进行检测,结果见下表1、表2。
表1实验前小鼠血糖水平
组别 | 空腹血糖值(mmol/L) | 餐后2小时血糖值(mmol/L) |
对照组 | 10.7±0.25 | 13.1±0.18 |
实施例1剂量组 | 11.2±0.12 | 13.9±0.14 |
实施例1高剂量组 | 10.9±0.28 | 13.4±0.25 |
实施例2剂量组 | 11.5±0.31 | 14.2±0.23 |
实施例2高剂量组 | 11.3±0.16 | 13.7±0.13 |
实施例3剂量组 | 10.7±0.32 | 13.6±0.32 |
实施例3高剂量组 | 11.2±0.18 | 14.5±0.64 |
实施例4剂量组 | 10.3±0.74 | 13.2±0.24 |
实施例4高剂量组 | 11.5±0.66 | 14.6±0.36 |
对比例1剂量组 | 10.7±0.52 | 13.5±0.42 |
对比例1高剂量组 | 11.3±0.44 | 14.2±0.28 |
对比例2剂量组 | 10.8±0.24 | 13.2±0.34 |
对比例2高剂量组 | 11.4±0.62 | 13.8±0.42 |
对比例3剂量组 | 11.6±0.12 | 14.3±0.18 |
对比例3高剂量组 | 10.9±0.28 | 13.7±0.24 |
表2实验后血糖水平
由上述表1、表2可知,实施例1~4中,实施例3降血糖效果最佳,为最佳实施例。并且实施例3降血糖效果远高于对比例1~3。因此,本发明产品具有显著的辅助降血糖功效。
试验例2
选择经饮食控制或口服降糖药治疗后病情较稳定,不需要更换药物品种及剂量,仅服用维持量的成年II型糖尿病且有胆囊炎并发症的400例患者,即空腹血糖≥7mmol/L(126mg/dl)或餐后2h血糖≥11.1mmol/L(200mg/dl);也可选择空腹血糖5.6~7mmol/L(100~126mg/dl)或餐后2h血糖7.8~11.1mmol/L(140~200mg/dl)的糖调节受损(IGR)人群。
治疗方法:参照原来生活习惯规定相应的饮食,试食期间坚持饮食控制,治疗糖尿病的药物种类和剂量不变。
将上述400例患者随机分为对照组、实施例1~4和对比例1~3共8组,每组50人,试食组在服药的基础上,按推荐服用方法服用量每日服用受试样品,对照组在服药的基础上可服用安慰剂或采用空白对照。用温水冲服实施例1~4及对比例1~3的辅助降血糖产品,每日2次即早晚各一次,每次1袋(每袋30g),时间2个月。
评价标准:
降血糖效果评价标准:
有效:(1)试验后空腹血糖恢复正常(≤5.6mmol/L),或空腹血糖下降幅度≥10%
(2)试验后餐后2h血糖恢复正常(≤7.8mmol/L),或餐后2h血糖下降幅度≥10%
无效:临床症状、体征均无明显改善,甚或加重;空腹血糖及餐后2小时血糖无下降,或下降未达到有效标准,糖化血红蛋白值无下降,或下降未达到有效标准。
胆囊炎效果评价标准:
发病次数减少、疼痛程度减轻即为有效;症状毫无缓解,即为无效。
试验结果:
试验结果如下表3所示
表3不同谷物粉对治疗糖尿病和胆囊炎的情况
由上表可知,本发明实施例1~4谷物粉不仅对糖尿病患者血糖降低有显著作用,而且还对高血压、糖尿病并发症胆囊炎症状具有有效缓解作用。
临床典型病例:
病例1:崔某,男,62岁,退休工人,属于高血糖、高血压人群,且视力开始模糊,平时空腹血糖是7.9mmol/L,餐后血糖为12.6mmol/L,服用实施例3的谷物粉,服用两月后,空腹血糖7.2mmol/L,餐后血糖为11.4mmol/L,且其血压明显降低,视网膜病变明显改善,视力明显改善。
病例2:李某,女,55岁,家庭主妇,糖尿病人群,伴有胆囊炎和视网膜病变,吃药并注射胰岛素进行治疗,每天需要注射26个单位的胰岛素,正常治疗并服用实施例3的谷物粉,服用两月后,胰岛素只需注射12个单位,胆囊炎和视网膜病变有明显缓解。
病例3:陈某,男,45岁,公司职工,糖尿病人群,伴有胆囊炎,平时空腹血糖是8.2mmol/L,餐后血糖为13.1mmol/L。服用实施例1的谷物粉,服用两月后,空腹血糖为7.1mmol/L,餐后血糖为12.1mmol/L,且胆囊炎有所缓解。
Claims (10)
1.一种含低聚木糖的谷物粉,其特征在于,由以下原料重量百分比制成的:燕麦粉15-20份、山药粉10-15份、葛根粉8-12份、桑叶粉8-12份、抗性糊精6-10份、木糖醇6-10份、菊粉6-10份、L-阿拉伯糖6-10份、枸杞粉3-7份、大豆肽2-5份、低聚木糖95粉2-5份、魔芋胶1-4份、维生素B6 0.1-0.5份、维生素E 0.1-0.5份、富硒酵母2-6份、硫酸锰0.01-0.05份、葡萄糖酸锌0.02-0.06份、富铬酵母0.002-0.004份。
2.根据权利要求1所述的含低聚木糖的谷物粉,其特征在于,由以下原料重量百分比制成的:燕麦粉18份、山药粉12份、葛根粉9份、桑叶粉8份、抗性糊精8份、木糖醇7份、菊粉6份、L-阿拉伯糖6份、枸杞粉5份、大豆肽4份、低聚木糖95粉4份、魔芋胶3份、维生素B6 0.3份、维生素E 0.3份、富硒酵母4份、硫酸锰0.05份、葡萄糖酸锌0.05份、富铬酵母0.004份。
3.根据权利要求1所述的含低聚木糖的谷物粉,其特征在于,由以下原料重量百分比制成的:燕麦粉16份、山药粉13份、葛根粉10份、桑叶粉10份、抗性糊精6份、木糖醇8份、菊粉8份、L-阿拉伯糖8份、枸杞粉6份、大豆肽3份、低聚木糖95粉5份、魔芋胶2份、维生素B6 0.1份、维生素E 0.5份、富硒酵母3份、硫酸锰0.03份、葡萄糖酸锌0.04份、富铬酵母0.003份。
4.一种如权利要求1所述的含低聚木糖的谷物粉制备方法,其特征在于,步骤如下:取葛根、山药、枸杞、桑叶,混合粉碎,加水浸泡,回流提取,过滤得提取液,提取液经浓缩、喷雾干燥即可得到成品;然后与燕麦粉、L-阿拉伯糖、低聚木糖和菊粉、抗性糊精、木糖醇、L-阿拉伯糖、大豆肽、低聚木糖、魔芋胶、维生素B6、维生素E、富硒酵母、硫酸锰、葡萄糖酸锌、富铬酵母按比例混合,混匀,即得。
5.根据权利要求4所述的含低聚木糖的谷物粉制备方法,其特征在于,所述药材粉碎粒度为20-30目。
6.根据权利要求4所述的含低聚木糖的谷物粉制备方法,其特征在于,加水水量与葛根、山药、枸杞、桑叶的粉粹混合物的质量比为5-7:1,浸泡时间为30-60min。
7.根据权利要求4所述的含低聚木糖的谷物粉制备方法,其特征在于,所述回流提取时间为30-40min。
8.根据权利要求1~3任一所述的含低聚木糖的谷物粉在制备辅助降血糖功能食品中的应用。
9.根据权利要求8所述的应用,其特征在于,在制备辅助治疗2型糖尿病及其并发症功能食品中的应用。
10.根据权利要求9所述的应用,其特征在于,所述2型糖尿病并发症为胆囊炎。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810564003.6A CN109221898A (zh) | 2018-06-04 | 2018-06-04 | 一种含低聚木糖的谷物粉及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810564003.6A CN109221898A (zh) | 2018-06-04 | 2018-06-04 | 一种含低聚木糖的谷物粉及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109221898A true CN109221898A (zh) | 2019-01-18 |
Family
ID=65083791
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810564003.6A Pending CN109221898A (zh) | 2018-06-04 | 2018-06-04 | 一种含低聚木糖的谷物粉及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109221898A (zh) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109673986A (zh) * | 2019-01-28 | 2019-04-26 | 广州佳明食品科技有限公司 | 一种葛根复合粉及其制备方法 |
CN109771578A (zh) * | 2019-02-02 | 2019-05-21 | 西安力邦制药有限公司 | 防治糖尿病及并发症的组合物 |
CN110150450A (zh) * | 2019-06-19 | 2019-08-23 | 烟台新时代健康产业有限公司 | 一种改善胆囊炎病症的特膳食品 |
CN110754660A (zh) * | 2019-11-22 | 2020-02-07 | 山东寡糖谷生物科技有限公司 | 一种降血糖复合全蚕粉寡糖代餐粉及其制造方法 |
CN110973603A (zh) * | 2019-11-22 | 2020-04-10 | 苏州隆欣达生物科技有限公司 | 一种治疗糖尿病的绿色食品及其制备工艺 |
CN111000119A (zh) * | 2019-09-19 | 2020-04-14 | 皈元(广州)健康文化传播有限公司 | 一种沙棘破壁燕麦粉及其生产工艺 |
CN111345467A (zh) * | 2020-03-18 | 2020-06-30 | 西安市如优商贸有限责任公司 | 膳食补充剂、制剂及其应用 |
CN111728214A (zh) * | 2020-08-13 | 2020-10-02 | 珠海市天顺保健食品有限公司 | 一种辅助逆转糖尿病的药食用组合物 |
CN113575838A (zh) * | 2021-07-22 | 2021-11-02 | 李香妹 | 一种富硒糖醇五谷代餐粉及其制备方法 |
CN114869995A (zh) * | 2022-03-24 | 2022-08-09 | 大医声科技(北京)有限公司 | 一种适用糖尿病患者多维营养素配方 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102246917A (zh) * | 2011-06-16 | 2011-11-23 | 杭州纸友科技有限公司 | 一种降血糖食品及其制备方法 |
CN104431741A (zh) * | 2015-01-14 | 2015-03-25 | 张桂英 | 一种谷物调理粥及其制备方法和用途 |
CN104543834A (zh) * | 2014-12-30 | 2015-04-29 | 山东龙力生物科技股份有限公司 | 一种具有降血糖功效的南瓜粉及其制备方法 |
US20150140178A1 (en) * | 2014-08-07 | 2015-05-21 | Mingfu LU | Complete Nutritional Powder and Preparation Method Thereof |
CN105410623A (zh) * | 2015-11-30 | 2016-03-23 | 谢晓亮 | 一种强化荞麦速食糊及其制备方法 |
CN106490614A (zh) * | 2016-10-31 | 2017-03-15 | 北京万源普达医疗科技有限公司 | 一种组合物及其作为糖尿病全营养配方食品的应用 |
CN106729092A (zh) * | 2016-12-29 | 2017-05-31 | 山东龙力生物科技股份有限公司 | 一种含低聚木糖的降血脂制剂及其制备方法和应用 |
CN107536057A (zh) * | 2017-10-23 | 2018-01-05 | 深圳联盛诺康控股有限公司 | 一种用于调理糖尿病患者的食品配方 |
-
2018
- 2018-06-04 CN CN201810564003.6A patent/CN109221898A/zh active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102246917A (zh) * | 2011-06-16 | 2011-11-23 | 杭州纸友科技有限公司 | 一种降血糖食品及其制备方法 |
US20150140178A1 (en) * | 2014-08-07 | 2015-05-21 | Mingfu LU | Complete Nutritional Powder and Preparation Method Thereof |
CN104543834A (zh) * | 2014-12-30 | 2015-04-29 | 山东龙力生物科技股份有限公司 | 一种具有降血糖功效的南瓜粉及其制备方法 |
CN104431741A (zh) * | 2015-01-14 | 2015-03-25 | 张桂英 | 一种谷物调理粥及其制备方法和用途 |
CN105410623A (zh) * | 2015-11-30 | 2016-03-23 | 谢晓亮 | 一种强化荞麦速食糊及其制备方法 |
CN106490614A (zh) * | 2016-10-31 | 2017-03-15 | 北京万源普达医疗科技有限公司 | 一种组合物及其作为糖尿病全营养配方食品的应用 |
CN106729092A (zh) * | 2016-12-29 | 2017-05-31 | 山东龙力生物科技股份有限公司 | 一种含低聚木糖的降血脂制剂及其制备方法和应用 |
CN107536057A (zh) * | 2017-10-23 | 2018-01-05 | 深圳联盛诺康控股有限公司 | 一种用于调理糖尿病患者的食品配方 |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109673986A (zh) * | 2019-01-28 | 2019-04-26 | 广州佳明食品科技有限公司 | 一种葛根复合粉及其制备方法 |
CN109771578A (zh) * | 2019-02-02 | 2019-05-21 | 西安力邦制药有限公司 | 防治糖尿病及并发症的组合物 |
CN110150450A (zh) * | 2019-06-19 | 2019-08-23 | 烟台新时代健康产业有限公司 | 一种改善胆囊炎病症的特膳食品 |
CN111000119A (zh) * | 2019-09-19 | 2020-04-14 | 皈元(广州)健康文化传播有限公司 | 一种沙棘破壁燕麦粉及其生产工艺 |
CN110754660A (zh) * | 2019-11-22 | 2020-02-07 | 山东寡糖谷生物科技有限公司 | 一种降血糖复合全蚕粉寡糖代餐粉及其制造方法 |
CN110973603A (zh) * | 2019-11-22 | 2020-04-10 | 苏州隆欣达生物科技有限公司 | 一种治疗糖尿病的绿色食品及其制备工艺 |
CN111345467A (zh) * | 2020-03-18 | 2020-06-30 | 西安市如优商贸有限责任公司 | 膳食补充剂、制剂及其应用 |
CN111728214A (zh) * | 2020-08-13 | 2020-10-02 | 珠海市天顺保健食品有限公司 | 一种辅助逆转糖尿病的药食用组合物 |
CN113575838A (zh) * | 2021-07-22 | 2021-11-02 | 李香妹 | 一种富硒糖醇五谷代餐粉及其制备方法 |
CN114869995A (zh) * | 2022-03-24 | 2022-08-09 | 大医声科技(北京)有限公司 | 一种适用糖尿病患者多维营养素配方 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109221898A (zh) | 一种含低聚木糖的谷物粉及其制备方法和应用 | |
CN102406860B (zh) | 预防和治疗糖尿病的组合物、其制备方法及应用 | |
CN100579395C (zh) | 一种具有稳定餐后血糖的方便营养粥及其制备方法 | |
CN101919530B (zh) | 一种茶及其制备方法 | |
CN106174585A (zh) | 降血糖的组合物及降血糖的复合益生菌特膳食品 | |
CN106360310A (zh) | 一种降低餐后血糖的组合物及其应用 | |
CN102526478B (zh) | 一种增强免疫力、降血糖功能的保健药物配方 | |
CN102526479B (zh) | 一种增强免疫力、降血糖功能的保健药物 | |
CN107212256A (zh) | 一种具有降血糖功能的代餐粉及其制备方法 | |
CN107198246A (zh) | 一种保健组合物与一种保健制剂 | |
CN103637185B (zh) | 神经酸组合物 | |
CN102113652A (zh) | 一种适合“五高”代谢综合症人群的特膳挤压米及其制备方法 | |
CN105661547A (zh) | 一种益生菌复配蚕桑的糖尿病人营养补充剂 | |
CN110710660A (zh) | 含有苦瓜粉的降低血糖组合物及膳食补充剂 | |
KR102408480B1 (ko) | 당뇨질환의 치료용 조성물 | |
CN105707378A (zh) | 黑青稞瘦身咖啡 | |
CN105613882A (zh) | 黑青稞降糖茶(奶茶) | |
CN1701716A (zh) | 降糖、降脂的保健食品及其制法 | |
CN111165709A (zh) | 一种具有血糖控制功能的固体饮料及其制备方法 | |
CN110432500A (zh) | 一种含菊粉的益生元组合物及制备方法和用途 | |
CN110693029A (zh) | 一种降血糖桑叶苦瓜功能食品 | |
CN106110294A (zh) | 一种修复受损胰岛细胞的营养制剂及其制备方法 | |
CN109043555A (zh) | 一种高血糖患者食用的特殊食品及其制备方法 | |
CN102150716B (zh) | 一种具有治疗糖尿病功能的茶剂及其制备方法 | |
CN103656624B (zh) | 一种复方蚕蛹降糖保健药物组合物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190118 |